IMPACT OF EXCLUSIVE HOSPITAL DISTRIBUTION OF BIOSIMILAR ON DRUG HEALTHCARE BUDGET
Author(s)
Rémuzat C*1;Vataire AL2;Cetinsoy L2;Aballea S1, Toumi M3 1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, PARIS, France, 3University Claude Bernard Lyon 1, Lyon, France
Presentation Documents
OBJECTIVES: There is an increased trend in shifting biologics distribution to exclusive hospital pharmacy channel. Although it looks obvious that such process will generate savings through tenders at regional or national level such policy consequences were not clearly quantified. We used a model developed for EU commission to assess the consequences of such policies on biosimilars for selected EU countries (model developed for the European Commission for the project”EU Pharmaceutical expenditure forecast” http://ec.europa.eu/health/healthcare/key_documents/index.en.htm). METHODS: We built a model to assess policy scenarios impact on pharmaceuticals reference forecast for seven EU Member States (France, the United Kingdom, Germany, Poland, Portugal, Greece and Hungary). We tested the impact of shifting biosimilar distribution to hospital channel on pharmaceutical industry revenue, Health insurers budget and society cost. RESULTS: For the period 2012-2016 the savings of biosimilars (based in million Euros) for Health insurance will be for: UK 2,023; GE 1,127; FR 1,634; PL 200; GR 19; PO 272; HU 29. The extra savings by shifting of the biosimilars distribution to exclusive hospital pharmacy will be: for UK 353; GE 3,392; FR 1,684; PL 37; GR 206; PO 65; HU 176. The difference is relatively small for UK, although significant. However, it is considerable for Germany and France (around 3 and 2 time original saving). Similar figures (revenue loss) are seen for pharmaceutical companies. CONCLUSIONS: Although the impact of such policy varies from one country to one another based on initial proportion of biosimilar distributed through hospital and level of discount over branded products, this policy appears to have a substantial impact on drug expenditures and might contribute to sustainability of health insurance in EU countries. Germany and France might benefit dramatically from such policy.
Conference/Value in Health Info
2013-11, ISPOR Europe 2013, The Convention Centre Dublin
Value in Health, Vol. 16, No. 7 (November 2013)
Code
BI4
Topic
Health Policy & Regulatory
Topic Subcategory
Reimbursement & Access Policy
Disease
Multiple Diseases